中年男性接种四价HPV疫苗后口腔HPV特异性抗体可持续30个月
本研究纳入美国坦帕和墨西哥库埃纳瓦卡150名27-45岁男性,在第1天、第2个月和第6个月接种四价HPV疫苗,并在第7、18、30个月采集血清和口腔漱口水检测抗HPV-16/18 IgG。结果发现第7个月时多数人口腔可检出抗体,但至第18和30个月口腔抗体可检出率下降;口腔与血清抗体水平呈强相关。
要点
- 中年男性接种四价HPV疫苗后,口腔HPV-16/18抗体可检出率随时间下降。
- 第7个月口腔HPV-16抗体可检出率为93.2%,HPV-18为72.1%。
- 口腔与血清HPV-16/18抗体水平高度相关(R2分别为0.93和0.91)。
核心结论
- 接种四价HPV疫苗后第18和30个月,口腔和血清HPV-16/18抗体可检出率下降。
- 当可检测到时,血清和口腔HPV-16/18抗体水平呈强相关。
研究设计与样本
- 研究纳入150名27-45岁男性,来自美国坦帕和墨西哥库埃纳瓦卡。
- 受试者在第1天、第2个月和第6个月接种四价HPV疫苗,共3剂。
- 在第7、18和30个月采集血清和口腔漱口水,用L1 VLP ELISA检测抗HPV-16和HPV-18 IgG抗体。
主要发现
- 所有参与者在第7个月均产生可检测的血清抗HPV-16和抗HPV-18抗体。
- 第7个月口腔漱口水中可检测到抗HPV-16抗体的比例为93.2%,抗HPV-18为72.1%。
- 第18和30个月口腔抗HPV-16抗体可检出率分别为39.8%和29.6%,抗HPV-18分别为10.7%和4.6%。
- 第7、18和30个月时,口腔HPV-16和HPV-18特异性抗体水平(归一化至总IgG)与血清水平相关,HPV-16的R2=0.93,HPV-18的R2=0.91。
临床怎么用
- 对于中年男性,四价HPV疫苗接种后口腔HPV抗体可检出率随时间下降,但口腔与血清抗体水平强相关,提示血清抗体或可反映口腔抗体水平。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HPV-16 and HPV-18 cause most oropharyngeal cancers, which are increasing in incidence among males. Although HPV vaccines are highly effective against a number of HPV-associated cancers, efficacy for oropharyngeal cancers has not yet been demonstrated. In addition, the level of antibodies required for protection against oral HPV infection is unknown. METHODS: 150 men ages 27-45 years from Tampa, FL, USA, and Cuernavaca, Mexico, received Gardasil at Day 1, Months 2, and 6. Then, sera and oral gargles were collected one month, 12 months, and 24 months after completion of the three doses (Month 7, 18 and 30 of the study) and tested for anti-HPV-16 and HPV-18 IgG antibody levels by a L1 VLP ELISA. RESULTS: All participants developed detectable serum anti-HPV-16 and anti-HPV-18 antibodies and most had detectable antibodies in oral gargles at Month 7 (HPV-16: 93.2%; HPV-18: 72.1%). By months 18 and 30, oral antibodies were detectable in a lower number of participants (HPV-16, 39.8% and 29.6%; HPV-18, 10.7% and 4.6% of individuals, respectively). Overall, oral HPV-16- and 18-specific antibody levels, normalized to total IgG at months 7, 18, and 30, correlated with serum levels (HPV-16, R2 = 0.93; HPV-18, R2 = 0.91). CONCLUSIONS: Reduced detectability of oral and serum HPV-16 and HPV-18 antibodies was observed at months 18 and 30 after initiation of the quadrivalent vaccination. However, when detectable, serum and oral HPV-16 and HPV-18 antibody levels were strongly correlated.
引用
- Parker KH, Kemp TJ, Isaacs-Soriano K, et al. HPV-specific antibodies at the oral cavity up to 30 months after the start of vaccination with the quadrivalent HPV vaccine among mid-adult aged men. Vaccine. 2019. PMID: 31005426. doi:10.1016/j.vaccine.2019.03.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。